LICENSED TECHNOLOGY

12 Months Ended

Dec. 31, 2014

NOTE 4 – LICENSED TECHNOLOGY

On September 22, 2014, we entered into an exclusive, worldwide, licensing agreement with Licensor to obtain rights to utilize and to sub-license to other pharmaceuticals firms, its patented methods for the extraction of therapeutic biologics from human plasma. Licensed technology consists of the following:

	December 31,
	2014		2013
Licensed technology	$	5,000,000	$	-
Less accumulated amortization		9,000		-
Licensed technology, net	$	4,991,000	$	-

Amortization on licensed technology was $9,000 and $0 for the years ended December 31, 2014 and 2013, respectively. The aggregate estimated amortization expense for intangible assets remaining as of December 31, 2014 is as follows:

2015	$	465
2016		465
2017		465
2018		465
2019		465
Thereafter		2,666
Total	$	4,991